Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F5AR
|
|||
| Drug Name |
Cibinetide
|
|||
| Synonyms |
UNII-9W5677JKDA; 9W5677JKDA; 1208243-50-8; Cibinetide [USAN]; Pglu-glu-gln-leu-glu-arg-ala-leu-asn-ser-ser; Pyr-glu-gln-leu-glu-arg-ala-leu-asn-ser-ser-OH; GTPL9677; CHEMBL3545305; DB13006; L-Serine, 5-oxo-L-prolyl-L-alpha-glutamyl-L-glutaminyl-L-leucyl-L-alpha-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-; L-Pyroglutamyl-L-glutamyl-L-glutaminyl-L-leucyl-L-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-L-serine; L-Pyroglutamyl-L-glutamyl-L-glutam
Click to Show/Hide
|
|||
| Indication | Depression [ICD-11: 6A70-6A7Z] | Phase 2 | [1] | |
| Neuropathic pain [ICD-11: 8E43.0] | Phase 2 | [2] | ||
| Sarcoidosis [ICD-11: 4B20.5; ICD-10: D86.3; ICD-9: 135] | Phase 2 | [3] | ||
| Diabetic macular edema [ICD-11: 9B71.02] | Phase 1 | [4] | ||
| Peripheral neuropathy [ICD-11: 8C0Z] | Phase 1 | [5] | ||
| Company |
Araim Pharmaceuticals Tarrytown, NY
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C51H84N16O21
|
|||
| Canonical SMILES |
CC(C)CC(C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CO)C(=O)O)NC(=O)C(C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C1CCC(=O)N1
|
|||
| InChI |
1S/C51H84N16O21/c1-22(2)17-30(47(84)65-32(19-36(53)71)48(85)66-33(20-68)49(86)67-34(21-69)50(87)88)63-40(77)24(5)57-41(78)25(7-6-16-56-51(54)55)59-43(80)29(11-15-39(75)76)62-46(83)31(18-23(3)4)64-45(82)27(8-12-35(52)70)60-44(81)28(10-14-38(73)74)61-42(79)26-9-13-37(72)58-26/h22-34,68-69H,6-21H2,1-5H3,(H2,52,70)(H2,53,71)(H,57,78)(H,58,72)(H,59,80)(H,60,81)(H,61,79)(H,62,83)(H,63,77)(H,64,82)(H,65,84)(H,66,85)(H,67,86)(H,73,74)(H,75,76)(H,87,88)(H4,54,55,56)/t24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
|
|||
| InChIKey |
WZTIQQBMSJTRBR-WYKNNRPVSA-N
|
|||
| CAS Number |
CAS 1208243-50-8
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Erythropoietin Receptor (EPOR) | Target Info | Agonist | [5] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Pathway Interaction Database | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
| EPO signaling pathway | ||||
| WikiPathways | EPO Receptor Signaling | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035038) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.